Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Hipofrakcjonowana radioterapia całej miednicy (WPRT) vs konwencjonalnie frakcjonowana radioterapia WPRT w raku prostaty (HOPE)

Czy hipofrakcjonowana radioterapia całej miednicy (WPRT) jest tak samo dobrze tolerowana jak konwencjonalnie frakcjonowana WPRT u pacjentów z rakiem prostaty? (HOPE-Trial)

The purpose of this research study is to determine if 5 (five) fractions of external radiotherapy with higher radiation doses per fraction to the pelvis leads to similar results to the standard of care external radiotherapy treatment that is comprised of 25 fractions of external radiotherapy with lower radiation doses per fraction to the pelvis.

This study aims to investigate the impact in quality of life associated with hypofractionated Whole Pelvis Radiotherapy (WPRT) in comparison to conventionally-fractionated WPRT in patients with unfavorable-intermediate and high-risk prostate cancers. This information is valuable as hypofractionated WPRT is a more attractive and convenient treatment approach, and may become the new standard of care if proven to be well-tolerated and effective. Therefore, this study aims to provide a more rational justification for use of hypofractionated WPRT in future larger randomized trials by comparing this strategy with the current standard of care. This study will also provide an initial understanding of the toxicity profile and cancer control associated with hypofractionated WPRT and High Dose Rate Brachytherapy (HDR-BT).

Przegląd badań

Typ studiów

Interwencyjne

Zapisy (Szacowany)

58

Faza

  • Faza 2

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
        • Tom Baker Cancer Centre
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
        • BC Cancer
    • Ontario
      • London, Ontario, Kanada, N6A 5W9
        • London Regional Cancer Program of the Lawson Health Research Institute

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Męski

Opis

Inclusion Criteria:

  • Age 18 or older
  • Study Informed Consent provided
  • Pathologically proven diagnosis of prostatic adenocarcinoma
  • Unfavorable intermediate risk [with greater than 15% chance of node involvement based on Memorial Sloan Kettering Cancer Center (MSKCC) nomogram https://www.mskcc.org/nomograms/prostate] or high or very-high-risk prostate cancer based on National Comprehensive Cancer Network (NCCN) classification [Prostatic Specific Antigen (PSA) > 20 ng/mL or clinical cT3a or cT3b or Gleason 8-10]
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • No prior history of pelvic irradiation, brachytherapy, cryosurgery, High-Intensity Focused Ultrasound (HIFU), Transurethral Resection of the Prostate (TURP) or radical prostatectomy

Exclusion Criteria:

  • Presence of nodal or distant metastasis, as confirmed by Magnetic Resonance Imaging (MRI) or Computerized Tomography (CT) of the chest/abdomen/pelvis and bone scan within 45 days of randomization
  • Plan for adjuvant docetaxel post-radiotherapy
  • Serious medical comorbidities or other contraindications to HDR-BT
  • Presence of inflammatory bowel disease
  • Presence of connective tissue disease
  • Medically unfit for general anesthesia
  • Unable or unwilling to complete questionnaires

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Conventionally-fractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 45 Gy WPRT in 25 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 45 Gy in 25 fractions WPRT

Eksperymentalny: Hypofractionated WPRT

15 Gy HDR brachytherapy boost will be administered followed by 25 Gy WPRT in 5 fractions. Androgen Deprivation Therapy (ADT) may also be prescribed at the discretion of the treating physician.

Total dose: 25 Gy in 5 fractions WPRT

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Quality of Life (QOL) - late bowel function as measured by the EPIC questionnaire
Ramy czasowe: I year post treatment (approximately 3 years and 2 months)

Late bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Quality of Life - acute urinary and sexual QOL as measured by the EPIC questionnaire
Ramy czasowe: 6 weeks post treatment (approximately 2 years and 3 months)

Acute urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) urinary and sexual domains. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - acute bowel toxicity as measured by the EPIC questionnaire
Ramy czasowe: 6 weeks post treatment (approximately 2 years and 3 months)

Acute bowel function as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) approximately 6 weeks after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

6 weeks post treatment (approximately 2 years and 3 months)
Quality of Life - late bowel bother as measured by the EPIC questionnaire
Ramy czasowe: I year post treatment (approximately 3 years and 2 months)

Late bowel bother as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC) sub-domain approximately 1 year after the end of treatment. The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
Quality of Life - late urinary and sexual QOL as measured by the EPIC questionnaire
Ramy czasowe: I year post treatment (approximately 3 years and 2 months)

Late urinary and sexual QOL as reported by the patient using the standardized questionnaire Expanded Prostate Cancer Index Composite (EPIC). The EPIC questionnaire contains 32 questions measuring patient function. Each question has a response option ranging from 0 or 1 (best) to 3, 4, or 5 (worst). The responses then correlate to a scoring scale of 0 to 100, where 0 is the best and 100 is the worst. The values vary from 0 to 100 for each question. The scores can then be added to come up with an overall quality of life score.

I year post treatment (approximately 3 years and 2 months)
International Prostate Symptom Score (IPSS)
Ramy czasowe: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

International Prostate Symptom Score (IPSS) as reported by the patient at 6 weeks, 1 year, and 2 years post treatment. The IPSS is a tool used for monitoring symptoms of prostate enlargement (benign prostatic hyperplasia). There are 7 questions related to urinary function. Responses are on a scale from 0 (best) to 5 (worst). Responses are added to come up with a total score, measuring if the patient is mildly symptomatic, moderately symptomatic, or severely symptomatic. There is 1 quality of life question related to urinary symptoms. Responses are on a scale from 0 (best) to 6 (worst).

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Toxicity - urinary, bowel, and sexual as measured by CTCAE version 4.0
Ramy czasowe: 6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)

Urinary, bowel, and sexual toxicity will be measured by the Common Terminology Criteria for Adverse Events (CTCAE) version 4, at 6 weeks, 1 year, and 2 years post treatment.

6 weeks post treatment (approximately 2 years and 3 months), 1 year post treatment (approximately 3 years and 2 months) and 2 years post treatment (approximately 4 years and 2 months)
Prostatic Specific Antigen (PSA) curve
Ramy czasowe: 4 years post treatment (approximately 6 years and 2 months)

PSA curve at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Prostatic Specific Antigen (PSA) Nadir
Ramy czasowe: 4 years post treatment (approximately 6 years and 2 months)

PSA nadir at 4 years post-treatment.

4 years post treatment (approximately 6 years and 2 months)
Cost Effectiveness of Hypofractionated WPRT
Ramy czasowe: End of study (approximately 7 years and 2 months)

Cost effectiveness analysis of the hypofractionated arm in comparison to the conventionally fractionated treatment arm.

End of study (approximately 7 years and 2 months)
Overall Survival
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to death from any cause.

End of study (approximately 7 years and 2 months)
Biochemical Failure-Free Survival
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to biochemical failure (based on the Phoenix definition) or death from any cause, whichever occurs first.

End of study (approximately 7 years and 2 months)
Freedom from Local Failure
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to first local failure.

End of study (approximately 7 years and 2 months)
Freedom from Regional Failure
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to first regional failure.

End of study (approximately 7 years and 2 months)
Androgen Deprivation Therapy Free Survival
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to start of salvage ADT, death or last follow-up.

End of study (approximately 7 years and 2 months)
Metastasis Free Survival
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to development of metastasis, death or last follow-up.

End of study (approximately 7 years and 2 months)
Prostate Cancer Free Survival
Ramy czasowe: End of study (approximately 7 years and 2 months)

The time from randomization to death attributed to prostate cancer.

End of study (approximately 7 years and 2 months)

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Lucas C Mendez, MD, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

7 lutego 2020

Zakończenie podstawowe (Szacowany)

1 września 2027

Ukończenie studiów (Szacowany)

1 marca 2028

Daty rejestracji na studia

Pierwszy przesłany

6 grudnia 2019

Pierwszy przesłany, który spełnia kryteria kontroli jakości

11 grudnia 2019

Pierwszy wysłany (Rzeczywisty)

12 grudnia 2019

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

1 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

30 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj